Abstracts tagged "prevention and treatment"

Abstract Number: 2572 • 2015 ACR/ARHP Annual Meeting
Protective and Therapeutic Effects of Growth Hormone on Collagen-Induced Arthritis
Ricardo J. Villares¹, Gabriel Criado², Rosa P Gomariz³, Yasmina Juarranz³, Javier Leceta³, Graciela Cascio⁴, Jose L. Pablos⁵ and Mario Mellado⁶, ¹Immunology & Oncology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain, ²Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ⁴Immunoloy & Oncology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain, ⁵Instituto de Investigacion Hospital, Madrid, Spain, ⁶Immunology and Oncology, Centro Nacional de Biotecnología. CNIC, Madrid, Spain
Background/Purpose: Inflammatory (M1) macrophages and T helper 17 (TH17) cells are central to rheumatoid arthritis (RA) pathogenesis. Although the growth hormone [GH]/insulin-like growth factor 1…
Abstract Number: 2730 • 2013 ACR/ARHP Annual Meeting
Netrin1 Is a Critical Autocrine Factor For Osteoclast Differentiation
Aranzazu Mediero¹, Bhama Ramkhelawon², Kathryn Moore², P. Edward Purdue³, Steven R. Goldring⁴ and Bruce N. Cronstein⁵, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ³Research, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Netrins have been extensively studied for their role in axonal guidance during neural development. In addition, netrins are chemopulsants for a variety of non-neuronal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].